Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | January 20, 2026 | January 21, 2026 |
| IGM Biosciences, Inc.IGMS · Entity 76422 | CHIEF MEDICAL OFFICER | September 13, 2024 | September 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date January 20, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2036-01-19 | Direct | 40,400 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 40,400 · Balance 40,400 F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.
IGM Biosciences, Inc.
Report date September 13, 2024 · Filed September 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154,331 |
Reported balance
After 2024-09-13 transaction · row 1
1 source rowRow 1 · 2024-09-13 · Sale · Disposed 1,487 · Balance 154,331 F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forty Seven, Inc.
Report date April 07, 2020 · Filed April 07, 2020
Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 1
1 source rowRow 1 · 2020-04-07 · Disposition to issuer · Disposed 3,906 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2026-02-25 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-07 · Disposition to issuer · Disposed 58,114 · Balance 0 F2: This option was canceled in the Merger in exchange for a cash payment of $5,432,787.29, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.88 · Expires 2027-08-14 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-07 · Disposition to issuer · Disposed 4,570 · Balance 0 F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $414,121.98, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2027-11-27 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-07 · Disposition to issuer · Disposed 70,398 · Balance 0 F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,352,011.54, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-26 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-07 · Disposition to issuer · Disposed 44,710 · Balance 0 F5: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $3,878,257.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.75 · Expires 2029-12-12 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-07 · Disposition to issuer · Disposed 113,153 · Balance 0 F6: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,760,891.75, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
F2: This option was canceled in the Merger in exchange for a cash payment of $5,432,787.29, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $414,121.98, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,352,011.54, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F5: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $3,878,257.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F6: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,760,891.75, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jan 21, 2026 21:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 40,400 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001193125-26-018022 · ownership.xml · derivative · entry 1 Takimoto Chris H · CIK 0001743780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 40,400 shares Expires 2036-01-19 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:27 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock (right to buy) · Derivative | 40,400 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-001977 · form4-01232025_110135.xml · derivative · entry 1 Takimoto Chris H · CIK 0001743780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 40,400 shares Expires 2035-01-20 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on February 21, 2025. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:55 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,487 | $11.54 | $17,158.20 |
DisclosureSEC source: 0001415889-24-023588 · form4-09182024_120952.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,331 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:44 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $68.01 | Not disclosed |
DisclosureSEC source: 0001415889-24-020005 · form4-07242024_120716.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2031-07-30 F2 · kind: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 150,000 shares of the Issuer's Common Stock and in exchange issued RSU grants of 43,750 shares and 16,250 shares. F2 · price: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 150,000 shares of the Issuer's Common Stock and in exchange issued RSU grants of 43,750 shares and 16,250 shares. F2 · derivative.exercise_date: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 150,000 shares of the Issuer's Common Stock and in exchange issued RSU grants of 43,750 shares and 16,250 shares. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:44 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 16,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-020005 · form4-07242024_120716.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,818 F3 · shares: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on January 19, 2026 and one-twelfth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. F2 · price: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 150,000 shares of the Issuer's Common Stock and in exchange issued RSU grants of 43,750 shares and 16,250 shares. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:44 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 43,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-020005 · form4-07242024_120716.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,568 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on July 19, 2025 and one-eighth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. F2 · price: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 150,000 shares of the Issuer's Common Stock and in exchange issued RSU grants of 43,750 shares and 16,250 shares. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 19:44 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,570 | $7.58 | $11,893.22 |
DisclosureSEC source: 0001415889-24-017500 · form4-06182024_110617.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,818 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $7.26 to $7.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 15, 2024 Filed Jun 18, 2024 19:44 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 3,000 | $5.02 | $15,060.00 |
DisclosureSEC source: 0001415889-24-017500 · form4-06182024_110617.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,388 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 19:55 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 2,535 | $10.17 | $25,782.22 |
DisclosureSEC source: 0001415889-24-008171 · form4-03152024_110357.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,388 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $9.80 to $10.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 19:55 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 2,889 | $9.88 | $28,529.45 |
DisclosureSEC source: 0001415889-24-008171 · form4-03152024_110357.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,923 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.625 to $10.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 18:25 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 92,500 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001415889-24-008056 · form4-03142024_100305.xml · derivative · entry 2 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2034-03-12 F2 · derivative.exercise_date: One forty-eighth of the shares subject to the option shall vest on April 12, 2024 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 18:25 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008056 · form4-03142024_100305.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,812 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-sixteenth of the RSUs shall vest on June 12, 2024 and each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 19:03 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,180 | $6.21 | $7,331.34 |
DisclosureSEC source: 0001209191-23-057113 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,562 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.79 to $6.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 23, 2023 Filed May 25, 2023 19:24 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 15 | $13.01 | $195.08 |
DisclosureSEC source: 0001209191-23-032306 · doc4.xml · nonDerivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,742 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F4 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 23, 2023 Filed May 25, 2023 19:24 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,244 | $12.30 | $15,301.82 |
DisclosureSEC source: 0001209191-23-032306 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,757 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 15, 2023 Filed May 25, 2023 19:24 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 962 | $11.71 | $11,265.02 |
DisclosureSEC source: 0001209191-23-032306 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,001 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:46 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001209191-23-023703 · doc4.xml · derivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2033-04-04 F2 · derivative.exercise_date: 1/48 of the shares subject to the option shall vest on April 12, 2023 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:46 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023703 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,039 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs shall vest on March 12, 2024 and each one-year anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 18:31 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,768 | $18.73 | $33,118.18 |
DisclosureSEC source: 0001209191-23-019421 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,789 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.34 to $19.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 20:12 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,938 | $19.36 | $37,518.71 |
DisclosureSEC source: 0001209191-22-062262 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,557 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.30 to $19.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 20:12 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 3,492 | $18.77 | $65,560.90 |
DisclosureSEC source: 0001209191-22-062262 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,495 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.29 to $19.289. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 20:31 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 277 | $21.99 | $6,091.62 |
DisclosureSEC source: 0001209191-22-058913 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,987 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.74 to $22.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 20:31 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 600 | $21.38 | $12,825.90 |
DisclosureSEC source: 0001209191-22-058913 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,264 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.74 to $21.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 24, 2022 Filed May 26, 2022 16:49 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 938 | $17.10 | $16,043.46 |
DisclosureSEC source: 0001209191-22-032233 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,864 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.79 to $17.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 13, 2022 Filed May 17, 2022 19:00 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 825 | $12.38 | $10,213.50 |
DisclosureSEC source: 0001209191-22-029860 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,802 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 18:44 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 14,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-019761 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,977 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs shall vest in December 2022, provided that the Reporting Person remains a service provider through the vesting date. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 20:55 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-22-019014 · doc4.xml · derivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-03-12 F2 · derivative.exercise_date: 1/48 of the shares subject to the option shall vest on April 12, 2022 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 20:55 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-019014 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs shall vest on March 12, 2023 and each one-year anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| November 15, 2021 Filed Nov 19, 2021 20:37 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065987 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs will vest on each of May 23, 2022, November 22, 2022, May 22, 2023, and November 22, 2023, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 17:42 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $68.01 | $0.00 |
DisclosureSEC source: 0001209191-21-049421 · doc4.xml · derivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-07-30 F1 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest on July 30, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person remaining a service provider through each such date. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:15 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 113,153 | Not disclosed Strike: $35.75 | Not disclosed |
DisclosureSEC source: 0001209191-20-023714 · doc4.xml · derivative · entry 6 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,153 shares Expires 2029-12-12 F6 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,760,891.75, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F6 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,760,891.75, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:15 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 44,710 | Not disclosed Strike: $8.76 | Not disclosed |
DisclosureSEC source: 0001209191-20-023714 · doc4.xml · derivative · entry 5 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,710 shares Expires 2028-04-26 F5 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $3,878,257.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F5 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $3,878,257.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:15 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 70,398 | Not disclosed Strike: $5.27 | Not disclosed |
DisclosureSEC source: 0001209191-20-023714 · doc4.xml · derivative · entry 4 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,398 shares Expires 2027-11-27 F4 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,352,011.54, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F4 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,352,011.54, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:15 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 4,570 | Not disclosed Strike: $4.88 | Not disclosed |
DisclosureSEC source: 0001209191-20-023714 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,570 shares Expires 2027-08-14 F3 · price: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $414,121.98, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F3 · derivative.exercise_date: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $414,121.98, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:15 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 58,114 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001209191-20-023714 · doc4.xml · derivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,114 shares Expires 2026-02-25 F2 · price: This option was canceled in the Merger in exchange for a cash payment of $5,432,787.29, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F2 · derivative.exercise_date: This option was canceled in the Merger in exchange for a cash payment of $5,432,787.29, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 12:15 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerCommon Stock | 3,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023714 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 2,797 | $0.00 Strike: $35.75 | $0.00 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · derivative · entry 11 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,153 Underlying: Common Stock · 2,797 shares Expires 2029-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments commencing on December 13, 2019, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 11,418 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · derivative · entry 10 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,710 Underlying: Common Stock · 11,418 shares Expires 2028-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments commencing on March 1, 2019, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 7,020 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · derivative · entry 9 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,398 Underlying: Common Stock · 7,020 shares Expires 2027-11-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments commencing on November 8, 2017, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · derivative · entry 8 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,570 Underlying: Common Stock · 8,333 shares Expires 2027-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments commencing on August 15, 2017, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 49,627 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · derivative · entry 7 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,114 Underlying: Common Stock · 49,627 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 79,195 | $95.42 | $7,556,786.90 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · nonDerivative · entry 6 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.411 to $95.43, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 2,797 | $35.75 | $99,992.75 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · nonDerivative · entry 5 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 11,418 | $8.76 | $99,993.14 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · nonDerivative · entry 4 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 7,020 | $5.27 | $36,995.40 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · nonDerivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,333 | $4.88 | $40,685.87 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 49,627 | $2.02 | $99,998.41 |
DisclosureSEC source: 0001209191-20-023395 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 3,906 shares acquired under the Forty Seven, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 19:28 UTC | Forty Seven, Inc. FTSV · Entity 16035 | GrantStock Option (right to buy) · Derivative | 115,950 | $0.00 Strike: $35.75 | $0.00 |
DisclosureSEC source: 0001209191-19-061042 · doc4.xml · derivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,950 Underlying: Common Stock · 115,950 shares Expires 2029-12-12 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments beginning with the vesting commencement date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:57 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0001209191-19-060143 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:57 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 10,000 | $2.02 | $20,150.00 |
DisclosureSEC source: 0001209191-19-060143 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.